title: High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation.
abstract: Optimal numbers of CD34(+) cells to be reinfused in patients undergoing peripheral blood progenitor cell (PBPC) transplantation after high-dose chemotherapy are still unknown. Hematologic reconstitution of 168 transplantations performed in patients with lymphoproliferative diseases was analyzed according to the number of CD34(+) cells reinfused. The number of days from PBPC reinfusion until neutrophil recovery (>1.0 x 10(9)/L) and unsustained platelet recovery (>50 x 10(9)/L) were analyzed in three groups defined by the number of CD34(+) cells reinfused: a low group with less than or equal to 2.5 x 10(6) CD34(+) cells/kg, a high group with greater than 15 x 10(6) CD34(+) cells/kg, and an intermediate group to which the former two groups were compared. The 22 low-group patients had a significantly delayed neutrophil (P < .0001) and platelet recovery (P < .0001). The 41 high-group patients experienced significantly shorter engraftment compared with the intermediate group with a median of 11 (range, 8 to 16) versus 12 (range, 7 to 17) days for neutrophil recovery (P = .003), and a median of 11 (range, 7 to 24) versus 14 (range, 8 to 180+) days for platelet recovery (P < .0001). These patients required significantly less platelet transfusions (P = .002). In a multivariate analysis, the amount of CD34(+) cells reinfused was the only variable showing significance for neutrophil and platelet recovery. High-group patients had a shorter hospital stay (P = .01) and tended to need fewer days of antibotic administration (P = .12). In conclusion, these results suggest that reinfusion of greater than 15 x 10(6) CD34(+) cells/kg after high-dose chemotherapy for lymphoproliferative diseases further shortens hematopoietic reconstitution, reduces platelet requirements, and may improve patients' quality of life.
authors.affiliation: Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France.
authors.forename: N
authors.initials: N
authors.lastname: Ketterer
authors.forename: G
authors.initials: G
authors.lastname: Salles
authors.forename: M
authors.initials: M
authors.lastname: Raba
authors.forename: D
authors.initials: D
authors.lastname: Espinouse
authors.forename: A
authors.initials: A
authors.lastname: Sonet
authors.forename: P
authors.initials: P
authors.lastname: Tremisi
authors.forename: C
authors.initials: C
authors.lastname: Dumontet
authors.forename: I
authors.initials: I
authors.lastname: Moullet
authors.forename: A
authors.initials: A
authors.lastname: Eljaafari-Corbin
authors.forename: E M
authors.initials: EM
authors.lastname: Neidhardt-Berard
authors.forename: F
authors.initials: F
authors.lastname: Bouafia
authors.forename: B
authors.initials: B
authors.lastname: Coiffier
mesh_terms: D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis*; D005260:Female; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D015999:Multivariate Analysis; D010976:Platelet Count; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D018952:Antigens, CD34